Added to YB: 2026-03-31
Pitch date: 2026-03-27
GSK [neutral]
GSK plc
+0.59%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 81.9B
Pitch Price
GBP 20.51
Price Target
N/A
Dividend
3.51%
EV/EBITDA
8.31
P/E
14.76
EV/Sales
2.93
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 27/3/2026 - GSK – Pipeline progress
GSK (update): Japan grants orphan designation for Ris-Rez in small-cell lung cancer (10-15% of lung cancers, 2nd most common in Japan), adding to US/EU designations. EMA accepted bepirovirsen for chronic hep B review (3.2m EU patients), potential first-in-class. Pipeline broadening addressable market not reflected in 10.5x 2027 EPS, 3.7% yield.
Read full article (1 min)